近日,根据NMPA官网的消息,亚盛医药万众期待的管线利沙托克拉片(APG-2575)已附条件批准上市,用于既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者。要知道,此前Bcl-2抑制剂全球仅有一款药物——维奈克拉,而此后,Bcl-2药物的研发热潮可以说持续了十年,如今,终于在亚盛医药这家biotech上开花结果。穿越...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.